BR112021018858A2 - Chiauranibe para tratamento de câncer de pulmão de células pequenas - Google Patents
Chiauranibe para tratamento de câncer de pulmão de células pequenasInfo
- Publication number
- BR112021018858A2 BR112021018858A2 BR112021018858A BR112021018858A BR112021018858A2 BR 112021018858 A2 BR112021018858 A2 BR 112021018858A2 BR 112021018858 A BR112021018858 A BR 112021018858A BR 112021018858 A BR112021018858 A BR 112021018858A BR 112021018858 A2 BR112021018858 A2 BR 112021018858A2
- Authority
- BR
- Brazil
- Prior art keywords
- chiauranib
- lung cancer
- small cell
- cell lung
- treatment
- Prior art date
Links
- 206010041067 Small cell lung cancer Diseases 0.000 title abstract 4
- BRKWREZNORONDU-UHFFFAOYSA-N n-(2-aminophenyl)-6-(7-methoxyquinolin-4-yl)oxynaphthalene-1-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=C1C=CC=2)=CC=C1C=2C(=O)NC1=CC=CC=C1N BRKWREZNORONDU-UHFFFAOYSA-N 0.000 title abstract 4
- 208000000587 small cell lung carcinoma Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
chiauranibe para tratamento de câncer de pulmão de células pequenas. são revelados um método para tratar câncer de pulmão de células pequenas com o uso de chiauranibe e o uso de chiauranibe na preparação de um fármaco para tratar câncer de pulmão de células pequenas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910229379 | 2019-03-25 | ||
PCT/CN2020/079822 WO2020192506A1 (zh) | 2019-03-25 | 2020-03-18 | 西奥罗尼用于小细胞肺癌的治疗 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021018858A2 true BR112021018858A2 (pt) | 2022-01-11 |
Family
ID=72611382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021018858A BR112021018858A2 (pt) | 2019-03-25 | 2020-03-18 | Chiauranibe para tratamento de câncer de pulmão de células pequenas |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220184055A1 (pt) |
EP (1) | EP3949966A4 (pt) |
JP (1) | JP7278405B2 (pt) |
KR (1) | KR20210141643A (pt) |
CN (2) | CN111728974B (pt) |
AU (1) | AU2020248270B2 (pt) |
BR (1) | BR112021018858A2 (pt) |
CA (1) | CA3134156C (pt) |
MX (1) | MX2021011529A (pt) |
TW (2) | TW202332445A (pt) |
WO (1) | WO2020192506A1 (pt) |
ZA (1) | ZA202107342B (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202332445A (zh) * | 2019-03-25 | 2023-08-16 | 大陸商深圳微芯生物科技股份有限公司 | 西奧羅尼用於小細胞肺癌的治療 |
CN116637182A (zh) * | 2022-02-24 | 2023-08-25 | 康方药业有限公司 | 包含抗ctla4-抗pd-1双特异性抗体和西奥罗尼的药物组合 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101906076B (zh) * | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
CN105481778B (zh) * | 2014-09-16 | 2019-06-04 | 深圳微芯生物科技股份有限公司 | 嘧啶衍生物、其制备方法及其应用 |
CN111065411B (zh) * | 2017-11-16 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 |
TW202332445A (zh) * | 2019-03-25 | 2023-08-16 | 大陸商深圳微芯生物科技股份有限公司 | 西奧羅尼用於小細胞肺癌的治療 |
TWI798532B (zh) * | 2019-03-25 | 2023-04-11 | 大陸商深圳微芯生物科技股份有限公司 | Kdm5a基因和atrx基因的應用 |
-
2020
- 2020-02-26 TW TW111147052A patent/TW202332445A/zh unknown
- 2020-02-26 TW TW109106185A patent/TWI797426B/zh active
- 2020-03-18 US US17/442,631 patent/US20220184055A1/en active Pending
- 2020-03-18 JP JP2021556944A patent/JP7278405B2/ja active Active
- 2020-03-18 CA CA3134156A patent/CA3134156C/en active Active
- 2020-03-18 WO PCT/CN2020/079822 patent/WO2020192506A1/zh unknown
- 2020-03-18 KR KR1020217033987A patent/KR20210141643A/ko active IP Right Grant
- 2020-03-18 AU AU2020248270A patent/AU2020248270B2/en active Active
- 2020-03-18 BR BR112021018858A patent/BR112021018858A2/pt unknown
- 2020-03-18 EP EP20776399.6A patent/EP3949966A4/en active Pending
- 2020-03-18 MX MX2021011529A patent/MX2021011529A/es unknown
- 2020-03-24 CN CN202010213256.6A patent/CN111728974B/zh active Active
- 2020-03-24 CN CN202210824941.1A patent/CN115105501A/zh active Pending
-
2021
- 2021-09-29 ZA ZA2021/07342A patent/ZA202107342B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021011529A (es) | 2021-12-15 |
CN111728974A (zh) | 2020-10-02 |
TWI797426B (zh) | 2023-04-01 |
CN111728974B (zh) | 2022-08-16 |
CA3134156C (en) | 2024-01-16 |
AU2020248270B2 (en) | 2023-05-18 |
CN115105501A (zh) | 2022-09-27 |
CA3134156A1 (en) | 2020-10-01 |
JP2022527702A (ja) | 2022-06-03 |
ZA202107342B (en) | 2023-03-29 |
KR20210141643A (ko) | 2021-11-23 |
WO2020192506A1 (zh) | 2020-10-01 |
US20220184055A1 (en) | 2022-06-16 |
TW202034919A (zh) | 2020-10-01 |
TW202332445A (zh) | 2023-08-16 |
JP7278405B2 (ja) | 2023-05-19 |
AU2020248270A1 (en) | 2021-10-28 |
EP3949966A4 (en) | 2022-12-28 |
EP3949966A1 (en) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112017019738A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
BR112017020952A2 (pt) | método de tratamento de câncer, composição e uso da composição | |
MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
BR112018068565A2 (pt) | combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos | |
BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
MX2020003959A (es) | Metodos terapeuticos relacionados con los inhibidores de hsp90. | |
BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
NZ750974A (en) | Antibody and checkpoint inhibitor combination therapy | |
CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
BR112014011925A2 (pt) | mutações no receptor notch humano e seu uso | |
MX2021006681A (es) | Anticuerpos anti-claudina y usos de los mismos. | |
ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
CL2019000846A1 (es) | Proteína terapéutica. | |
BR112021018858A2 (pt) | Chiauranibe para tratamento de câncer de pulmão de células pequenas | |
IL276406A (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos | |
EA201390287A1 (ru) | Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |